New combo tackles rare, tough kidney cancers
NCT ID NCT06302569
First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 30 times
Summary
This study tests two drugs, pembrolizumab and enfortumab vedotin, in people with rare kidney cancers (collecting duct carcinoma and renal medullary carcinoma) that have spread. About 23 adults will receive the treatment for several cycles, and doctors will check if their tumors shrink or stop growing. The goal is to see how well the combination works and how long it keeps the cancer under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL MEDULLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fondazione Irccs Istituto Dei Tumori Di Milano
RECRUITINGMilan, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.